Oppenheimer Raises Capricor Therapeutics (NASDAQ:CAPR) Price Target to $15.00

Capricor Therapeutics (NASDAQ:CAPR) had its price objective raised by Oppenheimer from $14.00 to $15.00 in a research note published on Tuesday morning, Benzinga reports. Oppenheimer currently has an outperform rating on the biotechnology company’s stock.

Other equities research analysts have also recently issued reports about the company. HC Wainwright reissued a buy rating and set a $40.00 price objective on shares of Capricor Therapeutics in a research note on Tuesday. Maxim Group reiterated a buy rating and issued a $12.00 target price on shares of Capricor Therapeutics in a report on Tuesday. One research analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. Based on data from MarketBeat.com, Capricor Therapeutics currently has an average rating of Moderate Buy and a consensus target price of $20.00.

Capricor Therapeutics Stock Performance

Shares of NASDAQ:CAPR opened at $5.08 on Tuesday. The firm has a market cap of $162.45 million, a price-to-earnings ratio of -5.84 and a beta of 3.92. The firm has a fifty day moving average price of $4.34 and a 200 day moving average price of $5.18. Capricor Therapeutics has a fifty-two week low of $2.68 and a fifty-two week high of $7.28.

Capricor Therapeutics (NASDAQ:CAPR) last released its quarterly earnings data on Wednesday, August 7th. The biotechnology company reported ($0.35) EPS for the quarter, missing the consensus estimate of ($0.32) by ($0.03). Capricor Therapeutics had a negative net margin of 102.93% and a negative return on equity of 220.27%. The company had revenue of $3.97 million for the quarter, compared to the consensus estimate of $4.51 million. As a group, research analysts predict that Capricor Therapeutics will post -1.24 earnings per share for the current year.

Institutional Trading of Capricor Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the business. Marshall Wace LLP bought a new position in shares of Capricor Therapeutics in the second quarter worth about $426,000. Renaissance Technologies LLC grew its stake in Capricor Therapeutics by 158.7% in the 2nd quarter. Renaissance Technologies LLC now owns 137,500 shares of the biotechnology company’s stock worth $656,000 after acquiring an additional 84,350 shares in the last quarter. Main Street Financial Solutions LLC grew its stake in Capricor Therapeutics by 37.5% in the 2nd quarter. Main Street Financial Solutions LLC now owns 27,500 shares of the biotechnology company’s stock worth $131,000 after acquiring an additional 7,500 shares in the last quarter. Rhumbline Advisers purchased a new position in shares of Capricor Therapeutics during the second quarter worth approximately $147,000. Finally, Bank of New York Mellon Corp raised its stake in shares of Capricor Therapeutics by 12.8% during the second quarter. Bank of New York Mellon Corp now owns 79,782 shares of the biotechnology company’s stock valued at $381,000 after acquiring an additional 9,040 shares in the last quarter. 21.68% of the stock is currently owned by institutional investors.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.